HR-4455 : Still Just a Bill

Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act

This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.

Action Timeline

Action DateTypeTextSource
2019-09-23CommitteeReferred to the Subcommittee on Health.House committee actions
2019-09-20CommitteeReferred to the Subcommittee on Health.House committee actions
2019-09-20IntroReferralReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.House floor actions
2019-09-20IntroReferralReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.House floor actions
2019-09-20IntroReferralIntroduced in HouseLibrary of Congress

Policy Area :

Health
See Subjects
  • Health care costs and insurance
  • Medicare
  • Prescription drugs
  • Product development and innovation

Related Bills

See Related Bills